155. Lancet and Statin in the Elderly

155. Lancet and Statin in the Elderly


https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0140673620322339?scrollTo=%23hl0000424

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32233-9/fulltext

do statins work in old people?? This study in the lancet says-

“In a contemporary primary prevention cohort, people aged 70–100 years with elevated LDL cholesterol had the highest absolute risk of myocardial infarction and atherosclerotic cardiovascular disease and the lowest estimated NNT in 5 years to prevent one event.’

researchers calculated that 80 adults aged 80–100 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and145 adults aged 70–79 years — would need to receive a moderate-intensity statin for 5 years to prevent one MI.
and to prevent just one ASCVD event, the numbers needed to treat were 42 and 88, respectively.

But anytime you read the results you have to say “how did you come up with that number” what were your methods?

In this study they took a sample of people from a large Danish database and these were low risk individuals not on statin therapy. They calculated the number of reduced events by calculating the event rate they expected and dividing it by the number of events during the follow up.

But remember youi have to ask how did you come up with your calculation???

“For these calculations, we assumed 30% and 22% relative risk reduction of myocardial infarction and atherosclerotic cardiovascular disease, respectively, per 1·0 mmol/L reduction in LDL cholesterol in individuals free of atherosclerotic cardiovascular disease, as observed in the Cholesterol Trialist Collaboration meta-analyses.”

THIS IS FRUSTRATING because if you have read the cholesterol trialist you collaboration you know that the individuals in the studies were HONDA they were not low risk individuals. The higher the risk you are the more likely a drug is to work. Think about it like this a statin is more likely to work on someone who is really high risk because they are way more likely to have a MACE. Just like breast cancer chemo therapy is more likely to work on someone who has breast cancer and is even more likely to work if the person is a women.

So in this study they estimated the event rate based on really sick people and then said based on that we can say the likelihood for benefit in these more healthy patients would have a benefit or NNT of 42 or 80 to prevent just one MACE.

NOOOOO you cant take the odds of sick people or people with breast cancer and then say well look how it worked in them so it must work the same way in this population over here.


Do the trial of statins in the elderly or don’t publish the paper

Episoder(385)

Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations

Episode 302: 301. Development and Validation of the American Heart Association's PREVENT Equations

At change in c stats of 0.007 or 0.0009 is not a meaningful change so I cant say we should use this over the PCE—yes this new calculator has the benefit of removal of race, and the use race-based algo...

12 Jun 202411min

Episode 301: 300. A New Trial On Beta Blockers and COPD

Episode 301: 300. A New Trial On Beta Blockers and COPD

The problems with observation data is real—  randomized trial, U.K. researchers identified 519 patients (mean age, 68) with mostly moderate COPD (mean forced expiratory volume in 1 second [FEV1], 50%)...

11 Jun 20246min

Episode 300: 299. When Do You Use a Cluster RCT?

Episode 300: 299. When Do You Use a Cluster RCT?

When you want to do an RCT but you realize there might be some cross contamination so instead of randomizing individuals you randomize cluters or groups Lets say you want to do fluids--- what is bette...

7 Jun 202414min

Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet

Episode 299: 298. Do We Have a Reversal Drug for DOACs? ANNEXA or Andexanet

1° outcome: hemostatic efficacy = which was defined as;(A) Hematoma expansion ≤ 35% at 12h(B) increase in NIHSS ≤ 7 at 12h(C) No rescue therapy 3-12h    Results hemostatic efficacy: 76.7% andexanet vs...

6 Jun 20249min

Episode 298: 297. Which one of the CHADVASC is worse?

Episode 298: 297. Which one of the CHADVASC is worse?

In patients with atrial fibrillation (AF), how do CHA2DS2-VASc 1 subgroups compare with one another    64 141 patients with a first AF diagnosis  Patients were categorized as CHA2DS2-VASc 1 if they ha...

5 Jun 20244min

Episode 297: FIXED! 296. Is There a Drug That Will Keep Alcoholics Out of the Hospital?

Episode 297: FIXED! 296. Is There a Drug That Will Keep Alcoholics Out of the Hospital?

Bottom line Do I think if you stop drinking alcohol in the next thirty days you are less likely to come to the hospital for a heart attack? A stroke? Pneumonia? copd exacerbations or CHF exacerbations...

30 Mai 202418min

Episode 296: 295. What is the Best Blood Pressure In the Nursing Home?

Episode 296: 295. What is the Best Blood Pressure In the Nursing Home?

In a retrospective cohort study of Veterans Affairs (VA) nursing home residents during 2006 to 2019, researchers identified 13,000 residents who initiated a first or additional antihypertensive medica...

29 Mai 20247min

Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

Episode 295: 294. SGLT2 Inhibitors and Stage 5 CKD

SGLT-2 inhibitors have not been evaluated in patients with stage 5 CKD (CKD 5; eGFR, ≤15 mL/minute/1.73 m2). Investigators in Taiwan retrospectively assessed 5 years of outcome data for nearly 48,000 ...

28 Mai 20245min

Populært innen Helse

fastlegen
rss-gukild-johaug
hvordan-har-du-det-mann
lydartikler-fra-aftenposten
psykodrama
leger-om-livet
relasjonspodden-med-dora-thorhallsdottir-kjersti-idem
rss-garne-damer
foreldreradet
hormonelle-frida
morten-ramm-lar-kakla-ga-til-du-sovner
rss-lopedrommen
hjernesterk
klimaks
g-punktet
bak-fasaden-en-reise-i-livet-med-sykepleier-ine
hverdagspsyken
treningsprat
helsetipspodden
kjed-deg-i-sovn-verdens-kjedeligste-podcast